Archive | October, 2017

RESI JPM 2018 Early Bird Registration Is Open

26 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On January 9th, 2018, the Redefining Early Stage Investments (RESI) Conference will join the JPM fray again for our largest event yet in San Francisco.

In the last two RESI JPM conferences, we had to close registrations two weeks early as we’d reached capacity. In RESI JPM 2018, LSN is expecting to bring together 500+ fundraising CEOs and 500+ early stage investors from around the globe and host over 2000 scheduled and ad hoc meetings in one high energy day.

RESI JPM will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. Register early to secure your partnering meetings with investors and strategic partners that are a fit.

LSN Mapped the Life Science Infrastructure in NYC – Here’s What We Found

26 Oct

By Lucy Parkinson, Director of Research, LSN

When LSN decided to launch our first RESI NYC event, we knew that RESI would be part of a growing hub of resources dedicated to launching and supporting new biotech and medtech companies. The rise of NYC has been an ongoing story in the biotech world, and we’ve written before about how the city stands among the competitors to become North America’s third great life science hub.

For a long time, the New Jersey area has been a center for big pharma companies, and New York’s universities and research hospitals have long been a significant source of scientific breakthroughs in the life sciences. All told, we counted 80 pharma facilities, and almost all of these are located outside the city. Conversely, of the 32 relevant universities and research facilities plus 40 life science research nonprofits, most were within the city, as you can see in the image below. In the past, it’s been difficult for entrepreneurs to bridge that gulf between the creation of new technology and its commercialization.

Enter the bio-incubators and accelerator facilities, of which we found 16. Many of these are new facilities, as developers respond to the growing need for space to launch a new life science company in New York. The addition of this new infrastructure has made it much easier for entrepreneurs to start their operations – at RESI, our new panel called “Why NYC? Why Now?” will explore how this infrastructure has become a key building block for the city’s life science growth.

The other key factor required for NYC’s biotech scene to bloom? Capital. New York is awash with investment dollars, but in the past, little of that money has been focused on life science ventures specifically. Investors who are interested in biotech startups don’t necessarily have NYC on their map as a place to look for new companies. By bringing RESI to NYC and gathering together investors from all over the world, we hope to put New York firmly on the bio hub tour.

Hot Investor Mandate 1: Major Medical Device Corporation Invests in Series A – D Rounds

26 Oct

A global medical device company is looking for traditional M&A opportunities in mature businesses as well as strategic equity investments in early stage companies via a corporate venture fund, primarily focused on Series A through D rounds. Initial investments usually range from $2M – $3M with some capital reserved for follow on investments and are generally flexible in terms of structure, with no special rights attached. Although these investments are strategic in nature, the fund does look for financial returns. The firm looks to deploy around $20 – $30M annually into these early stage ventures, and is open to companies on a global basis.

The firm has four main business segments in orthopedic reconstruction, advanced wound management, sports medicine and ENT. The firm is open to any technologies within these areas, from services to medical devices and is beginning to look at healthcare IT solutions that have utility in these segments. The firm will look at technologies as early as prototype phase and looks to leverage their internal expertise to evaluate their viability. The company has no restrictions in terms of regulatory pathway and will look at class I through class III products.

The firm has preference for experienced management teams but has no strict company or management requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: